Acadia Pharmaceuticals (ACAD +13.2%) pushes to a new 52-week high today on the back of a Seeking...
Acadia Pharmaceuticals (ACAD +13.2%) pushes to a new 52-week high today on the back of a Seeking Alpha article touting the potential of it's experimental anti-psychotic drug pimavanserin. On September 5, ACAD announced the completion of patient enrollment in a phase III study of the drug for treating Parkinson's disease psychosis. If approved, it will be the first antipsychotic drug to receive such approval, and will likely be immediately embraced, and extensively prescribed.
From other sites
at Nasdaq.com (Mar 27, 2015)
at 4-traders.com (Mar 23, 2015)
at Zacks.com (Mar 13, 2015)
at MarketWatch.com (Mar 11, 2015)
at CNBC.com (Mar 11, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs